WCN26-6463 SAFETY AND PRELIMINARY EFFICACY FINDINGS FROM A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SETANAXIB IN PATIENTS WITH ALPORT SYNDROME

Read full text Summarise with VIRAT
Authors: Daniel Philip Gale, Irene Agraz, Zainab Arslan, Rafael José Esteban de la Rosa, Matthew D. Hall, Karel Krejčí, Enrique Morales, Roman Šafránek, V Tesař, Roser Torrá, Ondrej Viklicky, Carl Stefan Carlsson
+2 more AARON M. LEVINE, Rachel Lennon
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Alport syndrome is a rare genetic disease resulting from collagen IV abnormalities and is marked by interstitial fibrosis and declining kidney function. Fibrosis prevention may preserve kidney function. We report safety and preliminary efficacy findings with setanaxib, an enzyme-driven hydrogen peroxide-depleting agent with anti-fibrotic properties, in patients with Alport syndrome.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105394–105394
Publication date
25 March 2026
Language
EN